Table 2.

Participants’ specific and non-specific biological markers.

Marker / Level	N	Frequency	Percentage	Median	Q1, Q3
Non-specific markers
CRP	478			3.74	3.16, 13.2
Negative (<10)		327	68.4
Positive (10+)		151	31.6
Moderate (10–<20)		82	16.1
Frank (20–<100)		42	9.8
High (100+)		26	5.6
Not done	17
Prothrombin time (s)	372			11.90	10.5, 13.2
Low (<9.4)		1	0.3
Normal (9.4–12.5 s)		232	62.4
High (>12.5)		139	37.4
Not done	123
PTT (s)	374			31.4	25.7, 35.8
Low (<25)		25	6.7
Normal (25–37 s)		269	71.9
High (>37)		80	21.4
Not done	121
Neutrophils	482			3	2, 5
Lymphocytes	481			2	1, 3
Hemoglobin (g/dl)	486			11.6	10.4, 12.6
Specific markers
ADNA	493			517.9	315.7, 755.6
C3	485			0.89	0.67, 1.11
C4	485			0.17	0.10, 0.24
Rheumatoid factor	266			11.0	10.1, 11.5
Negative (<15 IU/ml)		232	87.2
Positive (>15 IU/ml)		34	12.8
ACL IgG	376
Negative (<15 IU/ml)		327	87.0
Weak positive (15–40 IU/ml)		23	6.1
Positive (>40 IU/ml)		26	6.9
ACL IgM	386
Negative (<15 IU/ml)		344	89.1
Weak positive (15–40 IU/ml)		34	8.8
Positive (>40 IU/ml)		8	2.1
β2-IgG	271
Negative (<15 U/ml)		212	78.2
Weak positive (15–<40 U/ml)		31	11.4
Positive (40–<80 U/ml)		9	3.3
Strongly positive (80+ U/ml)		19	7.0
β2-IgM	285
Negative (<15 U/ml)		260	91.2
Weak positive (15–<40 U/ml)		14	4.9
Positive (40–<80 U/ml)		9	3.2
Strongly positive (80+ U/ml)		2	0.7
Lupus anticoagulant	344
Normal (0–45 s)		272	79.1
High (>45 s)		72	20.9

ADNA, Anti-double stranded DNA; ACL, anticardiolipin; Beta-2 Glycoprotein 1 Antibodies, IgG and IgM.

Bold values correspond to the total of patients with available data in the given parameter.